5 Healthcare Stocks With ‘Sick’ Revenue Growth Rates

The stocks on our list have significantly increased revenue figures compared to last year

SmallCapPower | August 10, 2016: Revenue growth is extremely important in the healthcare space as it shows if there is prominent demand for the product(s) or not. The five healthcare stocks on our list today have experienced a strong increase in revenue year-over-year.

Win Big With Our Small Cap Picks

 

SciVacConcordia International Corp. (TSE:CXR) – $21.82
Pharmaceuticals

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.

  • Market Cap: 1,112,007,321
  • Revenues: 3,279,264,000
  • Operating Income: 137,030,000
  • Revenue Growth YoY: 138%

SciVacKnight Therapeutics Inc. (TSE:GUD) – $8.35
Pharmaceuticals

Knight Therapeutics Inc. is a specialty pharmaceutical company. Its principal business activity is developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. The Company finances other life sciences companies in Canada and internationally with the goal of earning interest income and securing product distribution rights for Canada and select international markets.

  • Market Cap: 1,108,060,314
  • Revenues: 1,857,670
  • Operating Income: 26,023,430
  • Revenue Growth YoY: 412%

SciVacPatient Home Monitoring Corp. (CVE:PHM) – $0.23
Healthcare Facilities & Services

Patient Home Monitoring Corp is engaged in providing in-home monitoring equipment, supplies and services to patients in the United States. It is also engaged in offering a range of services to patients in need of chronic disease management, as well as acquiring other companies operating in the United States healthcare service and product sectors. The Company’s services include Respiratory Disease Management, including COPD; Equipment Solutions; Sleep Apnea & PAP Treatment; Oxygen Therapy; Respiratory Equipment Rental, and INR Self-Testing. It employs home ventilators, including the Trilogy 100 & ResMed Astral.

  • Market Cap: 215,285,203.21
  • Revenues: 122,790,780
  • Operating Income: – 42,474,270
  • Revenue Growth YoY: 100%

SciVacMerus Labs International Inc. (TSE:MSL) – $1.63
Pharmaceuticals

Merus Labs International Inc. (Merus) is a specialty pharmaceutical company. It is engaged in the acquisition and licensing of branded prescription pharmaceutical products in Canada and internationally. It carries out business principally in Canada and Europe. The Company has products in the area of urology/women’s health and anti-infectives.

  • Market Cap: 114,570,744.63
  • Revenues: 61,279,360
  • Operating Income: 164,300
  • Revenue Growth YoY: 91%

SciVacNeptune Technologies & Bioressources Inc. (TSE:NTB) – $1.35
Biotechnology & Medical Research

Neptune Technologies & Bioressources Inc. is a solution provider of omega-3’s and other functional ingredients to branded marketers in the nutraceutical industry, primarily in North America. The Company is engaged in the development, manufacture and commercialization of marine-derived omega-3 fatty acids. The Company’s products include Krill-Based Nutraceutical Products, including Neptune Krill Oil (NKO), OCEANO3, Formulations Derived from NKO and Neptune Krill Aquatein (NKA); Other Nutraceutical Products, and Pharmaceutical Product Candidate (CaPre)-Acasti.

  • Market Cap: 105,153,841
  • Revenues: 31,185,310
  • Operating Income: – 11,057,030
  • Revenue Growth YoY: 118%

DISCLAIMER
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.